Form 4: Medtronic EVP Kiil Exercises Options, Sells Shares

Medtronic plc's EVP and President of Cardiovascular, Harry Skip Kiil, executed pre-planned transactions, exercising stock options and selling ordinary shares.

Summary

• Harry Skip Kiil, Medtronic plc's EVP & President Cardiovascular, engaged in pre-planned transactions under a Rule 10b5-1 plan on February 19, 2026.
• Exercised stock options to acquire a total of 50,876 ordinary shares at exercise prices of $93.08 (30,568 shares), $87.76 (19,923 shares), and $80 (385 shares).
• Sold a total of 52,524 ordinary shares at weighted average prices ranging from $97.60 to $97.86.
• Following these transactions, direct beneficial ownership stands at 32,768 ordinary shares.
• Beneficial ownership also includes 239 shares acquired through dividend reinvestment since the last report.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While there's a net sale of shares, it's a pre-planned transaction for executive compensation and liquidity, not necessarily a bearish signal.

Positives

• The transactions were conducted under a Rule 10b5-1 plan, indicating they were pre-planned and not reactive trading based on immediate non-public information.
• The executive exercised options, demonstrating value in the company's stock at the exercise prices.
• The sale prices ($97.60 $97.86) are higher than the exercise prices ($80 $93.08), indicating a profitable transaction for the executive.

Negatives

• The executive sold a significant number of shares (52,524), slightly more than the shares acquired through option exercise, resulting in a net reduction of direct beneficial ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that executive stock option exercises and subsequent sales are common practices for compensation and liquidity, especially when executed under a Rule 10b5-1 plan, which aims to mitigate concerns about insider trading by pre-scheduling transactions.

Comparison to Industry Standards

• StockSavvy.ai observes that the exercise of stock options and subsequent sale of shares by executives is a standard component of executive compensation packages across the healthcare and medical device industry.
• This type of transaction, particularly when executed under a 10b5-1 plan, aligns with common practices seen at peer companies like Johnson & Johnson (JNJ) or Abbott Laboratories (ABT), where executives regularly manage their equity holdings for diversification and tax planning.

Related Party Transactions

• Harry Skip Kiil, an executive of Medtronic plc, engaged in transactions involving the company's ordinary shares and stock options.

Stakeholder Impact

• Shareholders may view the executive's sale of shares as a routine liquidity event, especially given the Rule 10b5-1 plan, rather than a signal of lack of confidence in the company's future.
• Employees are not directly impacted by this specific transaction, but executive compensation practices can influence overall morale and retention.

Key Dates

Recommendation

This Form 4 filing details routine, pre-planned executive compensation transactions (option exercise and share sale) under a Rule 10b5-1 plan. It does not provide new fundamental information about Medtronic's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The net sale of shares is a common practice for executives managing their personal portfolios and tax obligations, rather than a strong bearish signal. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals.

Keywords

Medtronic, MDT, SEC Form 4, Insider Trading, Stock Options, Share Sale, Executive Compensation, Harry Skip Kiil, Rule 10b5-1